Boston, MA -- (SBWIRE) -- 07/27/2017 -- Prostate cancer is also known as carcinoma of the prostate is cancer of the prostate gland that affects only the male population. It is a slow progressive disease. CRPC is an inveterate stage of prostate cancer, in which almost 90% of individuals develop metastases, specifically in the skeleton. The major therapies involved in the treatment of CRPC are hormonal therapy and chemotherapy.

Technavio's analysts forecast the global castration-resistant prostate cancer treatment market to grow at a CAGR of 9.01% during the period 2017-2021.

Get More Details on this Report and a Full Table of Contents at Global Castration Resistant Prostate Cancer Treatment Market 2017-2021

Covered in this report

The report covers the present scenario and the growth prospects of the global castration resistant prostate cancer treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.

The market is divided into the following segments based on geography:

-Americas
-APAC
-EMEA

Technavio's report, Global Castration-Resistant Prostate Cancer (CRPC) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-Astellas Pharma
-Johnson & Johnson
-Sanofi
-Valeant

Other prominent vendors

-Active Biotech
-Advaxis
-ANI Pharmaceuticals
-Athenex
-Bavarian Nordic
-Bayer
-Bristol-Myers Squibb
-CureVac
-GlaxoSmithKline
-Innocrin Pharmaceutical
-Merck
-Myovant Sciences
-Northwest Biotherapeutics
-OncoGenex Pharmaceuticals
-Oncolytics Biotech
-Orion
-Sotio
-Madrigal Pharmaceuticals)
-Takeda Pharmaceutical
-Teva Pharmaceutical Industries

Market driver

-Physician's preference toward hormonal therapy
-For a full, detailed list, view our report

Market challenge

-High cost of treatment
-For a full, detailed list, view our report

Market trend

-Increasing consolidation in cancer treatment market
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2021 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Astellas Pharma, Johnson & Johnson, Sanofi, Valeant, Active Biotech, Advaxis, ANI Pharmaceuticals, Athenex, Bavarian Nordic, Bayer, Bristol-Myers Squibb, CureVac, GlaxoSmithKline, Innocrin Pharmaceutical, Merck, Myovant Sciences, Northwest Biotherapeutics, OncoGenex Pharmaceuticals, Oncolytics Biotech, Orion, Sotio, Madrigal Pharmaceuticals, Takeda Pharmaceutical, Teva Pharmaceutical Industries

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer Global Clinical Trials Review, H1, 2016
-Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016
-Global Prostate Cancer Drugs Market 2016-2020
-Global Cancer Vaccines Market to 2022 - Robust Growth Driven by Increasing Prevalence, New Therapeutic Vaccine Approvals and Strong Uptake of Treatments Targeting CD19
-Metastatic Hormone Refractory Prostate Cancer - Pipeline Review, H2 2016